Nevolat
Images for illustrative purposes only
Nevolat is a popular weight loss treatment that works alongside a healthy diet and exercise. It contains the active ingredient Liraglutide, which regulates blood sugar and reduces cravings associated with hunger.
If you struggle to maintain a healthy body weight, Nevolat can help curb cravings and support your weight loss journey.
- Once daily self-injections
- Cheaper generic version of Saxenda
- Reduces your cravings and supports weight loss
- Works when combined with a healthy lifestyle
* Some options are not available with your selection
* Select options above to enable
Nevolat
Strength: Nevolat 3ml Pen (3 Pack)
Looking for Next Day delivery?
Order before 15:30 for next day delivery on working days
Buy Nevolat Online
Nevolat is a prescription-only treatment that contains Liraglutide, a medication that mimics GLP-1 (glucagon-like peptide), a natural hormone responsible for regulating appetite.
Nevolat targets receptors in the brain that are responsible for sending hunger signals, reducing food intake, and contributing to weight loss.
When to Use Nevolat Weight Loss Injections?
Nevolat is a GLP-1 receptor agonist mimicking the naturally occurring hunger reduction hormone. When used in injections, it can reduce hunger and cravings, contributing to weight loss.
If any of the following apply, Nevolat may be a suitable treatment option:
You're an adult over 18 with a BMI of 30 or over (classed as obese), or you have a BMI of 27 and over and a weight-related condition (type 2 diabetes, sleep apnoea, high blood pressure).
A child over 12 is classed as obese and may benefit from the treatment.
As a prescription treatment, Nevolat isn't available over the counter, and you'll need to complete an in-depth assessment before our pharmacists will prescribe it.
Age Restrictions
Nevolat is mostly available for adults over 18 with a high BMI, but it may be used in adolescents over 12 in some cases. However, the child must have a high BMI and weight of at least 60kg to use the treatment.
If a doctor feels it might benefit a young person, they'll discuss the potential risks and ensure it's the right decision.
How to Use a Nevolat Pen?
When using Nevolat injections, please follow these steps to ensure safety:
- Prepare: Always store new pens in the fridge. Check whether the liquid in the pen is clear, as expired pens might be cloudy. Wash your hands and attach a disposable needle to the pen.
- Flow Check: Follow the instructions in the leaflet to check the pen's flow and ensure it's working correctly.
- Set The Dose: You can set your dose by turning the dose selector. Please only take the prescribed amount and never increase the dose without medical advice.
- Injection: The best places to inject Nevolat include the upper arm, thighs and abdomen. It's best to rotate injection sites to avoid inflammation and irritation.
- Dispose: Cover the needle with the cap and dispose of it in a specialist sharps container.
Remember, Nevolat is a daily injection and using it at the same time each day ensures you stick to a routine. When prescribed the treatment, you'll begin with a low dose of 0.6 mg and gradually increase it to the maintenance dose of 3.0 mg.
When to Avoid Using Nevolat for Weight Management?
Liraglutide is a powerful weight loss treatment, but it's not suitable for everyone. If any of the following apply, you should avoid using Nevolat:
- Allergies: If you're sensitive or allergic to any of Nevolat's ingredients, you should avoid using it.
- Pregnancy and Breastfeeding: Nevolat isn't suitable if you're pregnant or breastfeeding. You should also avoid using it if you're planning to become pregnant.
- History of MTC): If you have a personal or family history of medullary thyroid carcinoma, you should avoid using the medicine, as it may increase your risk of developing thyroid tumours.
- Heart Failure: Nevolat may be unsuitable for patients with heart failure, although more research is needed to assess its potential effects.
- Type 1 Diabetes Mellitus: Nevolat isn't an insulin substitute, and patients with Type 1 diabetes should continue with their regular treatment schedule.
- Severe Renal & Hepatic Impairment: If you have severe renal or hepatic impairment, you should avoid using Nevolat.
Precautions
While the following doesn't automatically rule you out from using Nevolat, you should seek medical advice:
- Pancreatitis: Liraglutide can increase your risk of developing pancreatitis - especially if you have a history of the condition.
- Gastrointestinal Disease: If you have inflammatory bowel disease, you might need to avoid using Nevolat as it can worsen your symptoms.
- Thyroid Problems: Individuals with thyroid issues should be cautious when using Liraglutide.
- Seniors: There's limited research on whether Nevolat is suitable for people over 75.
- Other Medicines: If you're taking other medicines - including anticoagulants - you should speak to a doctor before using Nevolat.
- Other GLP-1s: You should never take Nevolat with other GLP-1 medicines, including lixisenatide and exenatide.
Ingredients
Nevolat contains the active ingredient of Liraglutide, which mimics the GLP-1 hormone. This is the key ingredient as it regulates your appetite and reduces food intake.
Inactive ingredients include:
- Propylene glycol
- Sodium citrate dihydrate
- Hydrochloric acid
- Phenol
- Water
- Sodium hydroxide
Side effects of Nevolat
As with all weight loss injection treatments, Nevolat can cause some side effects, ranging from mild to severe. It's important to monitor your symptoms and stop taking Nevolat if you experience the following severe side effects:
- Breathing problems
- Allergic reactions, including swelling of the throat and face
- Fast heartbeat
- Severe abdominal pain
- Pancreas inflammation
- Severe and persistent pain
Common/Mild Side Effects
- General nausea and potential vomiting
- Headaches
- Gastrointestinal issues (constipation/diarrhoea)
- Feeling tired and weak
- Dizziness
- Low blood sugar levels
- Alterations to your sense of taste
- Insomnia
- Rashes
These side effects are common when you begin taking the weight loss medication, and they should subside within a few days to a few weeks.
Uncommon Side Effects:
- Dehydration due to vomiting and diarrhoea
- Gall bladder inflammation
- Allergic reactions
- Fast pulse
- Kidney problems
- Bowel obstructions
Warnings
Pancreatitis
Acute pancreatitis has been observed in patients treated with GLP‑1 receptor agonists. It is essential that patients are educated about the classic symptoms—such as severe upper abdominal pain that may radiate to the back—so that they can seek immediate medical attention. If pancreatitis is suspected, liraglutide should be discontinued promptly. Once a diagnosis of acute pancreatitis is confirmed, re‑initiation of liraglutide is contraindicated.
References:
U.S. Food and Drug Administration (FDA) Drug Label Information [1]
European Medicines Agency (EMA) Product Information [2]
Cholelithiasis and Cholecystitis
Clinical trials for weight management have shown a higher incidence of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) in patients treated with liraglutide compared to placebo. Although rapid weight loss itself can increase the risk of gallstone formation, this factor only partially explains the elevated incidence seen with liraglutide. These complications can lead to hospitalisation and may require cholecystectomy. Patients should be informed about symptoms such as right upper quadrant pain, nausea, and vomiting.
References:
Peer‑reviewed clinical studies in Gastroenterology [3]
EMA safety communications [2]
Thyroid Disease
In clinical trials involving type 2 diabetes patients, thyroid-related adverse events, including goitre, have been reported—particularly in those with pre‑existing thyroid conditions. Liraglutide should therefore be used with caution in patients who have a history of thyroid disease.
References:
FDA Drug Safety Communication [1]
Endocrinology guidelines from the American Thyroid Association [4]
Heart Rate
An increase in heart rate has been consistently observed in clinical trials with liraglutide. Regular monitoring of heart rate is recommended as part of routine clinical practice. Patients should be advised to watch for signs such as palpitations or an abnormally fast heartbeat at rest. If a sustained and clinically significant increase in resting heart rate occurs, discontinuation of liraglutide should be considered.
References:
Cardiovascular outcome trials published in the New England Journal of Medicine [5]
FDA and EMA safety updates [1][2]
Risk of Aspiration with General Anaesthesia or Deep Sedation
Due to delayed gastric emptying associated with GLP‑1 receptor agonists, there is an increased risk of residual gastric content. This delay can heighten the risk of pulmonary aspiration during general anaesthesia or deep sedation. Healthcare providers should evaluate this risk before scheduling procedures requiring such sedation.
References:
Anesthesia safety guidelines from the American Society of Anesthesiologists [6]
Clinical pharmacology studies on gastric motility [7]
Dehydration
Gastrointestinal side effects (such as nausea, vomiting, and diarrhea) from GLP‑1 receptor agonists can predispose patients to dehydration, which in turn may lead to renal impairment or acute renal failure. Patients should be advised to maintain adequate fluid intake, especially if they experience significant gastrointestinal symptoms.
References:
Renal safety assessments in diabetes management literature [8]
FDA and EMA product information [1][2]
Hypoglycaemia in Type 2 Diabetes Mellitus
When liraglutide is used in combination with insulin and/or sulfonylureas, there is an increased risk of hypoglycaemia. To mitigate this risk, clinicians should consider reducing the dose of insulin and/or sulfonylureas. Patients must be informed about the signs of low blood sugar—such as shakiness, sweating, and confusion—and instructed on appropriate corrective actions.
References:
American Diabetes Association (ADA) Standards of Medical Care in Diabetes [9]
Clinical trial data from diabetes management studies [10]
Paediatric Population
Adolescents (aged ≥ 12 years) treated with liraglutide have experienced episodes of clinically significant hypoglycaemia. It is important that both patients and caregivers are educated about recognizing hypoglycaemic symptoms and are aware of the necessary steps to take should an episode occur.
References:
Pediatric endocrinology guidelines and clinical trial reports [11]
ADA recommendations [9]
Hyperglycaemia in Insulin‑Treated Patients with Diabetes Mellitus
Liraglutide (marketed as Nevolat in some regions) should not be used as a replacement for insulin in patients with diabetes mellitus. There have been reports of diabetic ketoacidosis following the rapid discontinuation or dose reduction of insulin. Thus, careful monitoring and appropriate insulin management remain critical.
References:
ADA Standards of Medical Care in Diabetes [9]
FDA prescribing information [1]
References
FDA Drug Label Information: FDA Official Website
European Medicines Agency (EMA) Product Information: EMA Official Website
Relevant clinical trial data published in Gastroenterology (for example, DOI: 10.1053/gastro.2015.03.020)
American Thyroid Association Guidelines: ATA Official Website
Cardiovascular outcome trials in the New England Journal of Medicine (for example, DOI: 10.1056/NEJMoa1403992)
American Society of Anesthesiologists – Anesthesia Safety Guidelines: ASA Official Website
Clinical studies on gastric emptying and GLP‑1 receptor agonists (for example, DOI: 10.1210/jc.2007-0222)
Renal safety assessments in diabetes literature (for example, DOI: 10.2337/dc13-1593)
American Diabetes Association (ADA) Standards of Medical Care in Diabetes: ADA Official Website
Clinical trial publications in diabetes management (for example, DOI: 10.1001/jama.2015.15854)
Pediatric endocrinology clinical guidelines (for example, DOI: 10.1111/pedi.12517)
Leaflets
Nevolat only works when combined with a balanced diet and exercise. If you're willing to make these changes, please complete an assessment today. A pharmacist will assess your eligibility for the treatment and then prescribe it.
Please read the Patient Information Leaflet before beginning your treatment, and get in touch with either your healthcare provider or our registered pharmacists with any questions.
